Eli Lilly & Co.

Leading Practices

• Eli Lilly is recognized for its efforts in assisting local generic partners in Index Countries produce its (now off-patent) TB medicines and complying with Good Manufacturing Practices (GMP).
• Eli Lilly is one of the only companies in the sector that has established an equitable pricing scheme for its Non-Communicable Disease products. The company sells its diabetes product, Humulin (vials) to the public health system in Least Developed Countries (LDCs) at prices that do not exceed 20% of the average price in North America, Western Europe and Japan. 

Changes Compared to Index 2008

• In November 2008, a shipment of Olanzapine (the generic version of Eli Lilly’s treatment for schizophrenia, Zyprexa®) from Indian company Cipla was seized in the Netherlands on its way to Peru based on European intellectual property laws. The shipment was detained for about eight months based on company request.

Suggested Areas for Improvement

• Eli Lilly’s ATM management system does not demonstrate comprehensive and systematic reporting of ATM initiatives, including the establishment of quantitative and qualitative targets at the project level.
• The company has limited in-house or collaborative R&D for Index Diseases other than TB. 
• Eli Lilly has lower-than-average transparency on its ATM strategy in several areas, particularly registration data for Index Disease products in Index Countries, donation programs, lobbying and advocacy and marketing activities in, or related to, ATM in Index Countries and resources dedicated to and output information for all ATM activities.